These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 4823822)

  • 21. [Hepatitis in haemophilia (author's transl)].
    Stampfli K
    Ther Umsch; 1979 Apr; 36(4):322-5. PubMed ID: 377555
    [No Abstract]   [Full Text] [Related]  

  • 22. Thrombogenicity associated with factor IX complex concentrates.
    Lusher JM
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):3-5. PubMed ID: 1780767
    [No Abstract]   [Full Text] [Related]  

  • 23. Biochemical and in vivo properties of high purity factor IX concentrates.
    Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
    Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy with factor IX concentrate resulting in DIC and thromboembolic phenomena.
    Campbell EW; Neff S; Bowdler AJ
    Transfusion; 1978; 18(1):94-7. PubMed ID: 625789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Merry christmas for patients with hemophilia B.
    Ponder KP
    N Engl J Med; 2011 Dec; 365(25):2424-5. PubMed ID: 22149960
    [No Abstract]   [Full Text] [Related]  

  • 26. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
    Santagostino E; Mannucci PM; Gringeri A; Tagariello G; Baudo F; Bauer KA; Rosenberg RD
    Thromb Haemost; 1994 Jun; 71(6):737-40. PubMed ID: 7974341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Purity of concentrates for substitution therapy: acceptable and undesirable contaminants--Madrid 1978.
    Scand J Haematol Suppl; 1980; 35():65-89. PubMed ID: 6770460
    [No Abstract]   [Full Text] [Related]  

  • 28. [Factor IX inhibitor in hemophilia B presented with anaphylactoid symptoms: report of 3 cases].
    Taketani T; Hanada R; Kawaguchi H; Ida K; Yamamoto K
    Rinsho Ketsueki; 1999 Oct; 40(10):1124-6. PubMed ID: 10565232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potentially thrombogenic materials in factor IX concentrates.
    Kingdon HS; Lundblad RL; Veltkamp JJ; Aronson DL
    Thromb Diath Haemorrh; 1975 Jun; 33(3):617-31. PubMed ID: 1154317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of a new concentrate for the treatment of factor IX deficiency.
    Gilchrist GS; Ekert H; Shanbrom E; Hammond D
    N Engl J Med; 1969 Feb; 280(6):291-5. PubMed ID: 5762370
    [No Abstract]   [Full Text] [Related]  

  • 31. Transfusion support for haemophiliacs.
    Allain JP
    Clin Haematol; 1984 Feb; 13(1):99-117. PubMed ID: 6426835
    [No Abstract]   [Full Text] [Related]  

  • 32. Obstetric care of the affected carrier of hemophilia B.
    Seeds JW; Cefalo RC; Miller DT; Blatt PM
    Obstet Gynecol; 1983 Sep; 62(3 Suppl):23s-25s. PubMed ID: 6877705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in the management of haemophilia and christmas disease.
    Biggs R
    Clin Haematol; 1979 Feb; 8(1):95-114. PubMed ID: 367667
    [No Abstract]   [Full Text] [Related]  

  • 34. Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction.
    Curry NS; Misbah SA; Giangrande PL; Keeling DM
    Haemophilia; 2007 May; 13(3):328-30. PubMed ID: 17498084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Substitution treatment of hemophilia a and b.
    Duckert F
    Schweiz Med Wochenschr; 1975 Jun; 105(24):783-4. PubMed ID: 1145162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro thrombogenicity tests of factor IX concentrates.
    Pepper DS; Banhegyi D; Howie A; Cash JD
    Br J Haematol; 1977 Aug; 36(4):573-83. PubMed ID: 889720
    [No Abstract]   [Full Text] [Related]  

  • 37. A trial of prophylactic replacement therapy in haemophilia and Christmas disease.
    Ramsay DM; Parker AC
    J Clin Pathol; 1973 Apr; 26(4):243-7. PubMed ID: 4701794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
    McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR
    Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Editorial: Clinical concentrates of clotting-factor IX.
    Lancet; 1975 Nov; 2(7940):855-6. PubMed ID: 53334
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.